Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 366-372

  Vassileva Pencheva, Ralitsa ^a   Galabov, Angel S ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Combinations; Coxsackievirus B1; Drug sensitivity; Mice; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; DISOXARIL; GUANIDINE; N PHENYL N' 3 HYDROXYPHENYLTHIOUREA; OXOGLAUCINE; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BRAIN INFECTION; BRAIN TISSUE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COXSACKIE VIRUS B; COXSACKIE VIRUS B1; COXSACKIE VIRUS INFECTION; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; EXPERIMENTAL INFECTION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MOUSE; NEWBORN; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SURVIVAL TIME; VIRUS ISOLATION;

ANIMALS; ANTI-RETROVIRAL AGENTS; BRAIN; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; ENTEROVIRUS B, HUMAN; INHIBITORY CONCENTRATION 50; MICE; MICROBIAL SENSITIVITY TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

COXSACKIEVIRUS; MUS;

EID: 74449090411     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.11.003     Document Type: Article

References (37)

1. Barnard D.L. Current status of anti-picornavirus therapies. Curr. Pharm. Des. 12 (2006) 1379-1390
2. Barnard D.L., Hubbard V.D., Smee D.F., Sidwell R.W., Watson K.G., Tucker S.P., and Reece P.A. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 48 (2004) 1766-1772
3. Barton D.J., and Flanegan J.B. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J. Virol. 71 (1997) 8482-8489
4. Beer K., and Geduldig L. ViroPharma Press Releases (2002). http://www.irconnect.com%3fvpharm/pages/news_release.html http://www.irconnect.com?vpharm/pages/news_release.html
5. Chumakov K., Ehrenfeld E., Wimmer E., and Agol V.I. Vaccination against polio should not be stopped. Nat. Rev. Microbiol. 5 (2007) 952-958
6. DeLong D.C., and Reed S.E. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J. Infect. Dis. 141 (1980) 87-91
7. De Palma A.M., Vliegen I., De Clercq E., and Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 28 (2008) 823-884
8. Diana G.D., McKinlay M.A., Otto M.J., Akullian V., and Oglesby C. [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. J. Med. Chem. 28 (1985) 1906-1910
9. Domingo E., Martin V., Perales C., and Escarmis C. Coxsackieviruses and quasispecies theory: evolution of enteroviruses. Curr. Top. Microbiol. Immunol. 323 (2008) 3-32
10. Eggers H.J. Successful treatment of enterovirus-infected mice by 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine. J. Exp. Med. 143 (1976) 1367-1381
11. Eigen M., and Biebricher C.K. Sequence space and quasispecies distribution. In: Domingo E., Holland J.J., and Ahlquist P. (Eds). RNA Genetics vol. 3 (1988), CRC Press, Boca Raton, FL 211-245
12. Fujita T. Concept of paraneurons. Arch. Histol. Jpn. 40 (1977) 1-12
13. Fujita T. Present status of paraneuron concept. Arch. Histol. Cytol. 52 (1989) 1-8
14. Fujita T., Kanno T., and Kobayashi S. The Paraneuron (1988), Springer-Verlag, Tokyo/Berlin/Heidelberg pp. 163-184
15. Galabov A.S. Thiourea derivatives as specific inhibitors of picornaviruses. Arzneimittelforschung 29 (1979) 1863-1868
16. Galabov A.S., and Velichkova E.H. Antiviral activity of N-phenyl-N′-aryl- or alkylthiourea derivatives in Coxsackie virus infections in mice. Antimicrob. Agents Chemother. 5 (1974) 1-18
17. Galabov A.S., and Dmitrieva T.M. Inhibitory effect of N-phenyl-N′-3-hydroxyphenylthiourea (PTU-23) on the reproduction of encephalomyocarditis virus in Krebs-II cells. Zentralbl. Bacteriol. Microbiol. Hyg. A 254 (1983) 291-305
18. Galabov A.S., Ginevskaya V.A., and Svitkin Yu.V. Effect of N-phenyl-N′-3-hydroxyphenylthiourea (PTU-23) on the protein synthesis in Krebs-II cells infected with encephalomyocarditis virus. Zentralbl. Bacteriol. Microbiol. Hyg. A 254 (1983) 306-317
19. Hadfield A.T., Diana G.D., and Rossmann M.G. Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 14730-14735
20. Hayden F.G., Hipskind G.J., Woerner D.H., Eisen G.F., Janssens M., Janssen P.A., and Andries K. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 39 (1995) 290-294
21. Herrmann E.C. Plaque-inhibition tests for detection of specific inhibitors of DNA containing viruses. Proc. Soc. Exp. Biol. 107 (1961) 142-145
22. Herrmann Jr. E.C., Herrmann J.A., and Delong D.C. Prevention of death in mice infected with coxsackievirus A16 using guanidine HCl mixed with substituted benzimidazoles. Antiviral Res. 2 (1982) 339-346
23. Hyöty H., Hiltunen M., Knip M., Laakkonen M., Vähäsalo P., Karjalainen J., Koskela P., Roivainen M., Leinikki P., Hovi T., et al. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 44 (1995) 652-657
24. Kunin C.M. Cellular susceptibility to enteroviruses. Bacteriol. Rev. 28 (1964) 382-390
25. Loddo B., Ferrari W., Brotzu G., and Spanedda A. In vitro inhibition of infectivity of polio viruses by guanidine. Nature 193 (1962) 97-98
26. McKinlay M.A., and Steinberg B.A. Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrob. Agents Chemother. 29 (1986) 30-32
27. Miller F.D., Monto A.S., DeLong D.C., Exelby A., Bryan E.R., and Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob. Agents Chemother. 27 (1985) 102-106
28. Nikolaeva-Glomb L., and Galabov A.S. Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus. Antiviral Res. 62 (2004) 9-19
29. Nikolaeva L., and Galabov A.S. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection. Acta Virol. 44 (2000) 73-78
30. Nikolaeva-Glomb L., Philipov S., and Galabov A.S. A new highly potent antienteroviral compound. In: Georgiev V.St. (Ed). National Institute of Allergy and Infectious Diseases, NIH, Frontiers in Research vol. I (2008), Humana Press Inc., Totowa, NJ 199-202
31. Nikolova I., and Galabov A.S. Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice. Antiviral Res. 60 (2003) 35-40
32. Pevear D.C., Tull T.M., Seipel M.E., and Groarke J.M. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43 (1999) 2109-2115
33. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., Van Weel C., and Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176 (2007) 532-555
34. Rossmann M.G. The structure of antiviral agents that inhibit uncoating when complexed with viral capsids. Antiviral Res. 11 (1989) 3-13
35. Siminoff P. A plaque suppression method for the study of antiviral compounds. Appl. Microbiol. 9 (1961) 66-72
36. Smith T.J., Kremer M.J., Luo M., Vriend G., Arnold E., Kamer G., Rossmann M.G., McKinlay M.A., Diana G.D., and Otto M.J. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233 (1986) 1286-1293
37. Teisner B., and Haahr S. Poikilothermia and susceptibility of suckling mice to Coxsackie B1 virus. Nature 247 (1974) 568